Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation
Published in
Gynecologic Oncology Reports, vol. 33, 100600Publication date
2020Abstract
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
TERZIC, Julie et al. Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. In: Gynecologic Oncology Reports, 2020, vol. 33, p. 100600. doi: 10.1016/j.gore.2020.100600
Main files (1)
Article (Published version)
Identifiers
- PID : unige:146865
- DOI : 10.1016/j.gore.2020.100600
- PMID : 32613071
